AcelRx Pharmaceuticals Inc (ACRX) Given Consensus Rating of “Buy” by Analysts
Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have earned an average rating of “Buy” from the ten brokerages that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.60.
Several brokerages have weighed in on ACRX. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 7th. Oppenheimer began coverage on shares of AcelRx Pharmaceuticals in a research report on Thursday, July 12th. They set a “hold” rating for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $6.00 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 2nd.
In related news, CEO Vincent J. Angotti bought 10,000 shares of the company’s stock in a transaction dated Tuesday, August 7th. The stock was purchased at an average cost of $2.90 per share, with a total value of $29,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Pamela P. Palmer bought 37,000 shares of the company’s stock in a transaction dated Monday, August 6th. The stock was bought at an average cost of $2.75 per share, with a total value of $101,750.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 57,300 shares of company stock valued at $159,552 in the last three months. 25.50% of the stock is currently owned by corporate insiders.
Shares of ACRX stock traded up $0.05 on Friday, hitting $3.25. 191,720 shares of the company’s stock traded hands, compared to its average volume of 418,834. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.96 and a current ratio of 4.01. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75. The firm has a market cap of $193.92 million, a P/E ratio of -2.95 and a beta of 2.09.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.93 million. analysts forecast that AcelRx Pharmaceuticals will post -0.77 EPS for the current year.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Featured Article: Technical Analysis
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.